본문
L&C Bio announced on the 12th that it will present the research findings of its knee cartilage treatment product MegaCarti® at the 2023 International Congress of the Korean Knee Society (ICKKS 2023).
MegaCarti® is a human-derived natural bone-based medical device designed to treat knee cartilage damage. Based on clinical trials conducted at four hospitals, the product received regulatory approval in Korea last November. The company plans to launch the product within the next few months through the New Health Technology Assessment (nHTA) exemption system.
The Korean Knee Society is a sub-society of orthopedics, consisting of over 1,700 knee specialists, and holds annual academic conferences. This year’s event marks the society’s 40th anniversary and is being held as an international congress at Seoul Dragon City Hotel from October 12 to 13.
L&C Bio is participating in the Industrial Symposium session of ICKKS 2023. The company will present its research results on MegaCarti® and share insights into its clinical efficacy.
The first lecture will be delivered by Professor Kimomo Chang (장기모) from Korea University Anam Hospital’s Department of Orthopedic Surgery, who participated in the MegaCarti® clinical trials. His presentation is titled, “MegaCarti®: A New Strategy for Knee Cartilage Regeneration.”
The second presentation will be given by L&C Bio’s Head of Research, Giwon Lee (이기원), under the theme “MegaCarti®: Launch of the World’s First Human-Derived Natural Bone-Based Knee Cartilage Repair Medical Device.”
L&C Bio CEO Hwancheol Lee commented, “L&C Bio has grown based on R&D and evidence-based clinical marketing. We will continue to take on new challenges without hesitation and work closely with orthopedic professionals to develop the next breakthrough after MegaCarti®.”
